The Canadian biotech company acquires the rights to drugs that are off-patent, approved, or near commercialization and reformulates them for new or expanded labels. They focus on the development of ophthalmic indications and commercialize drug candidates with a clinical history. iCo-008, a human monoclonal antibody targeting eotaxin-1, is one of their in-licensed assets. The company also uses drug delivery technologies such as sustained-release or biodegradable matrices to extend patent coverage. iCo Therapeutics operates in Canada and Australia.